CLAIMS

1. A monoclonal antibody that is capable of specifically binding the K2 domain of TFPI, wherein said antibody is capable of specifically binding an epitope comprising residue R17 of SEQ ID NO: 2.

2. A monoclonal antibody that is capable of specifically binding the K2 domain of TFPI, wherein said antibody is capable of binding an epitope comprising one or more residues selected from the group consisting of E10, E11, D12, P13, R17, Y19, T21, Y23, F24, N26, Q28, Q31, C32, E33, R34, F35, K36 and L50 of SEQ ID NO: 2.

3. A monoclonal antibody that is capable of binding the K2 domain of TFPI, wherein the light chain of said antibody comprises amino acid residues:
• E, in the position corresponding to position 31,
• S, in the position corresponding to position 32,
• D, in the position corresponding to position 33,
• Y, in the position corresponding to position 37,
• A, in the position corresponding to position 96,
• T, in the position corresponding to position 97 and
• F, in the position corresponding to position 99
of SEQ ID NO: 15;
and wherein the heavy chain of said antibody comprises amino acid residues:
• N, in the position corresponding to position 31,
• R, in the position corresponding to position 53,
• S, in the position corresponding to position 54,
• Y, in the position corresponding to position 57,
• Y, in the position corresponding to position 59,
• F, in the position corresponding to position 60,
• P, in the position corresponding to position 61,
• D, in the position corresponding to position 62,
• Q, in the position corresponding to position 65,
• Y, in the position corresponding to position 102,
• D, in the position corresponding to position 103 and
• D, in the position corresponding to position 106
of SEQ ID NO 18.

4. The monoclonal antibody according to claim 3, wherein said heavy chain further comprises an S in the position corresponding to position 52 of SEQ ID NO: 18 and/or wherein said light chain further comprises an H in the position corresponding to position 98 of SEQ ID NO: 15 and said heavy chain further comprises an S in the position corresponding to position 56 of SEQ ID NO: 18.

5. A monoclonal antibody that is capable of binding the Kunitz 2 (K2) domain of tissue factor pathway inhibitor (TFPI), wherein the heavy chain of said antibody comprises:
• a CDR1 sequence of amino acids 31 to 35 (NYAMS) of SEQ ID NO:18, wherein one of these amino acids may be substituted by a different amino acid; and/or
• a CDR2 sequence of amino acids 50 to 66 (TISRSGSYSYFPDSVQG) of SEQ ID NO:18, wherein one, two or three of these amino acids may be substituted by a different amino acid; and/or
• a CDR3 sequence of amino acids 99 to 110 (LGGYDEGDAMDS) of SEQ ID NO:18, wherein one, two or three of these amino acids may be substituted by a different amino acid.

6. A monoclonal antibody that is capable of binding the Kunitz 2 (K2) domain of tissue factor pathway inhibitor (TFPI), wherein the light chain of said antibody comprises:
• a CDR1 sequence of amino acids 24 to 39 (KSSQSLLESDGKTYLN) of SEQ ID NO: 15, wherein one, two or three of these amino acids may be substituted with a different amino acid; and/or
• a CDR2 sequence of amino acids 55 to 61 (LVSILDS) of SEQ ID NO: 15, wherein one or two of these amino acids may be substituted with a different amino acid; and/or
• a CDR3 sequence of amino acids 94 to 102 (LQATHFPQT) of SEQ ID NO: 15, wherein one or two of these amino acids may be substituted with a different amino acid.

7. A monoclonal antibody that is capable of binding the Kunitz 2 (K2) domain of tissue factor pathway inhibitor (TFPI), wherein the heavy chain of said antibody comprises:
• a CDR1 sequence of amino acids 31 to 35 (NYAMS) of SEQ ID NO:18 and
• a CDR2 sequence of amino acids 50 to 66 (TISRSGSYSYFPDSVQG) of SEQ ID NO:18 and
• a CDR3 sequence of amino acids 99 to 110 (LGGYDEGDAMDS) of SEQ ID NO:18
and wherein the light chain of said antibody comprises:
• a CDR1 sequence of amino acids 24 to 39 (KSSQSLLESDGKTYLN) of SEQ ID NO: 15; and
• a CDR2 sequence of amino acids 55 to 61 (LVSILDS) of SEQ ID NO: 15; and
• a CDR3 sequence of amino acids 94 to 102 (LQATHFPQT) of SEQ ID NO: 15.

8. A monoclonal antibody according to any one of the preceding claims, wherein the light chain of said antibody comprises SEQ ID NO: 15 and the heavy chain of said antibody comprises SEQ ID NO: 18.

9. A monoclonal antibody according to any one of the preceding claims, wherein the light chain of said antibody comprises SEQ ID NO: 21 and the heavy chain of said antibody comprises SEQ ID NO: 24.

10. A monoclonal antibody according to any one of the preceding claims, which is capable of binding the K2 domain of TFPI with a higher affinity than mAb2974.

11. A monoclonal antibody according to any one of the preceding claims that is capable of neutralising the TFPI inhibition of membrane-bound FVIIa/TF/FXa by at least 55%, such as at least 60%, such as at least 65%, such as at least 70%, such as at least 75%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as up to 100%, such as 100%, as measured in an FVIIa/TF/FXa inhibitor assay, when TFPI is staturated with said antibody.

12. A eukaryotic cell which expresses the monoclonal antibody, or fragment thereof, according to any one of claims 1-10.

13. A pharmaceutical composition comprising an antibody according to any one of claims 1-10 or a polynucleotide according to claim 11 and a pharmaceutically acceptable carrier or diluent.

14. Use of a monoclonal antibody according to any one of claims 1-10 for the treatment of a subject with a coagulopathy.

15. A method of treating a subject with a coagulopathy, comprising administering to said subject the m